Personalized dendritic cell vaccine for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have glioblastoma (a type of brain cancer) that has come back or worsened after standard treatment.
- You can still manage most daily tasks yourself (a score of 60 or higher on the Karnofsky scale).
- You have at least one measurable tumor on an MRI scan (at least 1 cm in size).
- You are not pregnant, and if you can have children, you agree to use birth control during the study and for 6 months after treatment.
- You have not had certain other treatments (like chemotherapy or targeted therapy) too recently before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
This trial tests a personalized vaccine made from your own immune cells that targets a protein (survivin) found on your tumor. It is given alongside the standard radiation and chemotherapy to see if it helps fight the cancer.
This trial tests an experimental immunotherapy made from your own immune cells, designed to train them to attack a protein (survivin) found in glioblastoma. It is a phase 1 study, meaning it is one of the first times this treatment is being tested in people, and it is given alongside standard radiation and chemotherapy.
This trial is testing a new vaccine (Bvax) added to the usual chemotherapy and radiation for glioblastoma. It aims to train your immune system to fight the tumor and possibly improve outcomes.
This trial tests a personalized vaccine made from your own immune cells (a dendritic cell vaccine) that may help your body fight the brain tumor. It is meant for people with DIPG or glioblastoma who have already tried standard treatments but still have tumors.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.